Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

Journal Article

2004

Permanent link to this Item
http://hdl.handle.net/11427/26733
Files
Van_Leth_Nevirapineefavirenz_2004.pdf (142.49 KB)
Authors
Van Leth, Frank
Phanuphak, Prahpan
Schechter, Mauro
Murphy, Robert L
Horban, Andrzej
Hall, David B
Lange, Joep M A
Reiss, Peter
Stroes, Erik
Gazzard, Brian
Cahn, Pedro
Raffi, François
Wood, Robin
Bloch, Mark
Katlama, Christine
Kastelein, John J P
Journal Title

PLOS Medicine

Link to Journal
http://journals.plos.org/plosmedicine/
Journal ISSN
Volume Title
Publisher
Publisher

University of Cape Town

Department
Division of Infectious Disease and HIV Med
Faculty
Faculty of Health Sciences
License
Series
Abstract
Patients infected with HIV-1 initiating antiretroviral therapy (ART) containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) show presumably fewer atherogenic lipid changes than those initiating most ARTs containing a protease inhibitor. We analyzed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV).
Description

Reference:

Van Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., ... & Schechter, M. (2004). Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS medicine, 1(1), e19.

Collections
Journal Articles